GBP109.56
2.27% yesterday
London, Sep 25, 05:38 pm CET
ISIN
GB0009895292
Symbol
AZN

AstraZeneca Stock price

GBP109.56
-10.12 8.46% 1M
-2.81 2.50% 6M
+7.10 6.93% YTD
-3.65 3.22% 1Y
+16.37 17.57% 3Y
+33.09 43.26% 5Y
+77.75 244.43% 10Y
+97.30 793.93% 20Y
London, Closing price Thu, Sep 25 2025
-2.54 2.27%
ISIN
GB0009895292
Symbol
AZN
Industry

Key metrics

Basic
Market capitalization
GBP174.5b
Enterprise Value
GBP193.7b
Net debt
GBP19.3b
Cash
GBP5.3b
Shares outstanding
1.6b
Valuation (TTM | estimate)
P/E
28.4 | 16.1
P/S
4.2 | 3.9
EV/Sales
4.6 | 4.3
EV/FCF
31.8
P/B
5.3
Dividends
DPS
GBP2.46
Yield 1Y | 5Y
2.2% | 2.5%
Growth 1Y | 5Y
7.8% | 2.4%
Payout 1Y | 3Y
73.3% | 92.0%
Increased
1 Year
Financials (TTM | estimate)
Revenue
GBP42.3b | GBP44.6b
EBITDA
GBP13.3b | GBP16.0b
EBIT
GBP10.3b | GBP14.0b
Net Income
GBP6.2b | GBP10.8b
Free Cash Flow
GBP6.1b
Growth (TTM | estimate)
Revenue
15.0% | 10.9%
EBITDA
27.4% | 30.2%
EBIT
37.0% | 48.9%
Net Income
28.8% | 105.8%
Free Cash Flow
17.5%
Margin (TTM | estimate)
Gross
82.1%
EBITDA
31.3% | 35.9%
EBIT
24.4%
Net
14.7% | 24.2%
Free Cash Flow
14.5%
Financial Health
Equity Ratio
39.2%
Return on Equity
17.3%
ROCE
17.5%
ROIC
14.5%
Debt/Equity
0.7
More
EPS
GBP4.0
FCF per Share
GBP4.0
Short interest
-
Employees
94k
Rev per Employee
GBP430.0k
Show more

Create a Free Account to create an AstraZeneca alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

AstraZeneca Stock Analysis

Unlock Scores for Free

Analyst Opinions

34 Analysts have issued a AstraZeneca forecast:

29x Buy
85%
5x Hold
15%

Analyst Opinions

34 Analysts have issued a AstraZeneca forecast:

Buy
85%
Hold
15%

Financial data from AstraZeneca

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
42,347 42,347
15% 15%
100%
- Direct Costs 7,591 7,591
16% 16%
18%
34,757 34,757
15% 15%
82%
- Selling and Administrative Expenses 11,705 11,705
2% 2%
28%
- Research and Development Expense 9,881 9,881
20% 20%
23%
13,271 13,271
27% 27%
31%
- Depreciation and Amortization 2,942 2,942
2% 2%
7%
EBIT (Operating Income) EBIT 10,330 10,330
37% 37%
24%
Net Profit 6,217 6,217
29% 29%
15%

In millions GBP.

Don't miss a Thing! We will send you all news about AstraZeneca directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

AstraZeneca Stock News

Neutral
Seeking Alpha
about 16 hours ago
Even with Trump's looming threats to impose tariffs on pharma imports, the performance of AstraZeneca's cardiovascular and oncology franchises continues to impress me. So, sales of Truqap, which continues to actively capture the breast cancer drugs market, reached $170 million in the second quarter of 2025, an increase of 84.8% year-on-year. Despite AstraZeneca's aggressive R&D policy, its EBIT...
Neutral
Business Wire
one day ago
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and Daiichi Sankyo's supplemental Biologics License Application (sBLA) for ENHERTU® (fam-trastuzumab deruxtecan-nxki) in combination with pertuzumab has been accepted and granted Priority Review in the US for the 1st-line treatment of adult patients with unresectable or metastatic HER2-positive breast cancer. The Food and Drug Administration (FDA) ...
Neutral
PRNewsWire
4 days ago
BOSTON , Sept. 22, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), an AI technology company transforming precision medicine, today announced an expansion of its collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) from the World CB & CDx Summit in Boston.
More AstraZeneca News

Company Profile

AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. Its pipeline are used for the following therapy areas: oncology, cardiovascular, renal, metabolism, and respiratory. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Head office United Kingdom
CEO Pascal Soriot
Employees 94,300
Founded 1992
Website www.astrazeneca.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today